Literature DB >> 31840223

Quantitative Prediction of Interactions Mediated by Transporters and Cytochromes: Application to Organic Anion Transporting Polypeptides, Breast Cancer Resistance Protein and Cytochrome 2C8.

Michel Tod1,2,3, Laurent Bourguignon4,5,6, Nathalie Bleyzac7, Sylvain Goutelle4,5,6.   

Abstract

BACKGROUND: The in vivo mechanistic static model (IMSM) is an effective method to predict the magnitude of drug-drug interactions (DDIs) mediated by cytochromes.
OBJECTIVE: The aim of this study was to extend the IMSM paradigm to DDIs mediated by organic anion transporting polypeptide (OATP) 1Bs, breast cancer resistance protein (BCRP) and cytochrome 2C8.
METHODS: First, a generic model for this kind of interaction was established, and a literature search was then conducted to retrieve the area under the concentration-time curve (AUC) ratio of a large set of DDIs involving OATP1B1, OATP1B3, BCRP and cytochromes 2C8 or 3A4. The model was fitted to the data to estimate the characteristic parameters (contribution ratios [CRs] and inhibition or induction potencies [IXs]) by nonlinear regression, and the model was qualified by external validation on a different dataset. Lastly, the model was used to identify the risks of overexposure by DDIs of this type.
RESULTS: A total of 27 substrates, 26 inhibitors, 3 inducers and 3 genetic variants were considered in the regression analysis. The number of observations (AUC ratios, denoted as Robs) was 101. Forty-six CRs and 47 IXs were estimated. The proportions of predictions within 0.67- to 1.5-fold and 0.5- to twofold Robs were 90% and 99%, respectively, for the internal validation, and 78% and 96%, respectively, for the external validation. The median fold-error was 1.03 (the ideal value is 1). The interquartile range of fold-error was 0.31, and the relative standard error of parameter estimates was, at most, 17%.
CONCLUSIONS: The IMSM approach was successfully extended to DDIs mediated by OATP1Bs, BCRP and cytochromes 2C8 or 3A4. The method revealed good predictive performances by internal and external validation.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31840223     DOI: 10.1007/s40262-019-00853-2

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  50 in total

1.  Transporter-mediated drug--drug interactions involving OATP substrates: predictions based on in vitro inhibition studies.

Authors:  K Yoshida; K Maeda; Y Sugiyama
Journal:  Clin Pharmacol Ther       Date:  2012-06       Impact factor: 6.875

Review 2.  The P-glycoprotein transport system and cardiovascular drugs.

Authors:  Jeffrey D Wessler; Laura T Grip; Jeanne Mendell; Robert P Giugliano
Journal:  J Am Coll Cardiol       Date:  2013-04-03       Impact factor: 24.094

3.  Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data.

Authors:  Hannah M Jones; Hugh A Barton; Yurong Lai; Yi-An Bi; Emi Kimoto; Sarah Kempshall; Sonya C Tate; Ayman El-Kattan; J Brian Houston; Aleksandra Galetin; Katherine S Fenner
Journal:  Drug Metab Dispos       Date:  2012-02-16       Impact factor: 3.922

Review 4.  Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.

Authors:  Qingcheng Mao; Jashvant D Unadkat
Journal:  AAPS J       Date:  2014-09-19       Impact factor: 4.009

Review 5.  Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.

Authors:  Mikko Niemi; Marja K Pasanen; Pertti J Neuvonen
Journal:  Pharmacol Rev       Date:  2011-01-18       Impact factor: 25.468

6.  Disposition pathway-dependent approach for predicting organic anion-transporting polypeptide-mediated drug-drug interactions.

Authors:  Zhe-Yi Hu
Journal:  Clin Pharmacokinet       Date:  2013-06       Impact factor: 6.447

Review 7.  Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1.

Authors:  R Elsby; C Hilgendorf; K Fenner
Journal:  Clin Pharmacol Ther       Date:  2012-10-10       Impact factor: 6.875

Review 8.  Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.

Authors:  Rui Li; Hugh A Barton; Manthena V Varma
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

Review 9.  Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption.

Authors:  Yoshihisa Shitara; Kazuya Maeda; Kazuaki Ikejiri; Kenta Yoshida; Toshiharu Horie; Yuichi Sugiyama
Journal:  Biopharm Drug Dispos       Date:  2013-01       Impact factor: 1.627

10.  Exogenous Cripto-1 Suppresses Self-Renewal of Cancer Stem Cell Model.

Authors:  Md Jahangir Alam; Ryota Takahashi; Said M Afify; Aung Ko Ko Oo; Kazuki Kumon; Hend M Nawara; Aprilliana Cahya Khayrani; Juan Du; Maram H Zahra; Akimasa Seno; David S Salomon; Masaharu Seno
Journal:  Int J Mol Sci       Date:  2018-10-26       Impact factor: 5.923

View more
  2 in total

1.  In Vitro Assessment of Transporter Mediated Perpetrator DDIs for Several Hepatitis C Virus Direct-Acting Antiviral Drugs and Prediction of DDIs with Statins Using Static Models.

Authors:  Xiaoyan Chu; Grace Hoyee Chan; Robert Houle; Meihong Lin; Jocelyn Yabut; Christine Fandozzi
Journal:  AAPS J       Date:  2022-03-21       Impact factor: 4.009

2.  Machine learning-based quantitative prediction of drug exposure in drug-drug interactions using drug label information.

Authors:  Ha Young Jang; Jihyeon Song; Jae Hyun Kim; Howard Lee; In-Wha Kim; Bongki Moon; Jung Mi Oh
Journal:  NPJ Digit Med       Date:  2022-07-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.